💊 Divi’s Laboratories – Short & Long Term View

📊 Technical Setup Stock is recovering from a recent downtrend channel, showing signs of reversal. RSI ~43 → bouncing from oversold zone, momentum improving. Strong support around ₹5,735–5,800 (channel base & OI put buildup). Resistance at ₹6,250–6,300, breakout here can trigger momentum toward ₹6,500+. Derivatives: Put writing at 6100, while call OI seen at 6200–6400, suggesting near-term consolidation but bullish bias above 6100. 🎯 Short-term Targets (2–4 wks): T1: ₹6,250 T2: ₹6,400 Extended: ₹6,550 🎯 Long-term Targets (6–12 mths): T1: ₹6,800 T2: ₹7,200+ (if global pharma sentiment improves). 📈 Fundamental View Divi’s Lab is a global leader in APIs & custom synthesis, strong reputation for quality and compliance. Growth drivers: demand in generics, expansion in contrast media APIs and contract manufacturing (CRAMS). Balance sheet is debt-free with healthy margins. Q1 saw moderate earnings but long-term outlook strong with recovery in export demand & specialty APIs. ⭐ Analyst View Brokerages maintain ACCUMULATE/HOLD with cautious optimism. Near-term upside capped until ₹6,300 is cleared decisively. Long-term view remains positive, supported by global positioning & strong balance sheet. ⚠️ Risks USFDA / regulatory inspection risks. Global pricing pressure in APIs. Slowdown in generics demand could impact near-term growth. ✅ Summary Divi’s Lab is showing early signs of trend reversal. Short-term upside toward ₹6,400–6,550, while long-term potential extends to ₹7,200+. Bias remains bullish above ₹5,735 support